NCT06574269View on ClinicalTrials.gov

A Study on TLC590 for Managing Postsurgical Pain

PHASE2RecruitingINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

September 30, 2024

Primary Completion Date

July 31, 2026

Study Completion Date

August 31, 2026

Conditions
Postsurgical Pain Management
Interventions
DRUG

TLC590

Sequentially enrolled into increasing dose cohorts from low to high to receive a dose of TLC590

DRUG

TLC590

TLC590 Dose 1

DRUG

TLC590

TLC590 Dose 2

DRUG

TLC590

The MTD of TLC590

DRUG

TLC590

TLC590 Dose 3 (The SMC-suggested dose)

DRUG

Ropivacaine

Ropivacaine

DRUG

TLC590

TLC590

Trial Locations (2)

77043

RECRUITING

Memorial Hermann Village, Houston

77401

RECRUITING

First Surgical Hospital, Bellaire

Sponsors
All Listed Sponsors
lead

Taiwan Liposome Company

INDUSTRY

NCT06574269 - A Study on TLC590 for Managing Postsurgical Pain | Biotech Hunter | Biotech Hunter